Business combination, contingent consideration, commercial milestone payments, payable.

No definition available.

Name:	goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business combination, contingent consideration, development and regulatory milestone payments, payable.

+ References

No definition available.

+ Details

Name:	goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business Combination Contingent Consideration Initial Phase Three Clinical Payments Payable

+ References

No definition available.

+ Details

Name:	goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business combination, contingent consideration, sales milestone payments, payable.

+ References

No definition available.

+ Details

Name:	goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Product license term.

+ References

No definition available.

+ Details

Name:	goss_ProductLicenseTerm
Namespace Prefix:	goss_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	goss_UpfrontPayment
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The net amount, measured at acquisition-date fair value, of all the assets acquired and liabilities assumed that arise from contingencies and were recognized by the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

+ Details

Name:	us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionAxis=goss_PulmokineIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=goss_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentSeralutinibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details) - Pulmokine, Inc. - License Agreement - Seralutinib - USD ($)		1 Months Ended
	Oct. 02, 2017	Oct. 31, 2017	Dec. 31, 2024	Jan. 31, 2024	Jan. 31, 2021
Business Acquisition [Line Items]
Product license term	10 years
Upfront payment		$ 5,500,000
Milestones accrued			$ 0	$ 10,000,000	$ 5,000,000
Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments	$ 48,000,000.0
Development and regulatory milestone payments, due upon the initiation of a phase 3 clinical trial	5,000,000.0
Commercial milestone payments, payable	45,000,000.0
Sales milestone payments, payable	$ 190,000,000.0